Navigation Links
Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
Date:7/25/2012

NEWARK, N.J., July 25, 2012 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that the Company made a regulatory milestone payment to Abbott Biotherapeutics Corp. following the launch of Actinium's multi-center Phase I/II clinical trial in acute myeloid leukemia (AML).  Acute Myeloid Leukemia is the most difficult form of leukemia to treat.  The majority of patients do not qualify for the commonly used chemotherapy regimen and their median survival following diagnosis is about two months without treatment.  The drug candidate being developed in this trial is Actimab-A, a construct developed using Lintuzumab, the monoclonal antibody licensed from Abbott Biotherapeutics Corp., formerly PDL, and Actinium's proprietary patented technology to deliver high doses of alpha irradiation directly to cancer cells while largely sparing healthy tissues.

"This payment reflects the significant progress our company has made over the last six months," said Dragan Cicic, MD, the CEO of Actinium Pharmaceuticals Inc.  "In addition to having successfully started our first multi-center trial, Actinium Pharmaceuticals is moving ahead with trial expansion and adding new product candidates.  We remain on track in our development plan and look forward to continuing to report further strategic milestones."

Under the terms of the Abbott Biotherapeutics license, Actinium Pharmaceuticals makes payments to Abbott Biotherapeutics when certain key regulatory milestones are reached and will also make royalty payments on the sales of Actimab-A. 

About Actimab-A

Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha
'/>"/>

SOURCE Actinium Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013  An international roster of experts on malignant ... Santa Monica, Calif. , to discuss ... MPM, a rare form of cancer that results from ... lining of the chest. Hosted by UCLA ... 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant ...
(Date:5/24/2013)... , May 24, 2013  Heska Corporation (NASDAQ: HSKA, ... and specialty products, announced today that Dr. Robert ... and Jason Napolitano , executive vice president ... Marcum MicroCap Conference, which is being held May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/24/2013)... , May 24, 2013 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... recently learned from a public announcement issued by Shanghai ... company listed on Shenzhen Stock Exchange, that on May ... ("Ms. Chan"), one of the shareholders of the ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4
... Sept. 26 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... trial of glufosfamide plus gemcitabine were presented at ... Spain. In the Phase 2 clinical trial ... of advanced pancreatic cancer, six-month and,one-year survival were ...
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... (Ibis), has been awarded a subcontract,of a National ... influenza,surveillance research through application of the Ibis T5000(TM) ... Ibis and the Lovelace,Respiratory Research Institute (LRRI) and ...
Cached Medicine Technology:Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 4Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 2Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 3Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 4Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies 5
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... Cellular Dynamics International (CDI) exclusive license rights to ... and regenerative medicine applications. These cells are capable of ... heart, including cardiomyocytes, endothelial cells, and vascular smooth muscle ... therapeutic for damaged heart tissue. , The original agreement ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 On May ... seventh commencement ceremony of American University of Antigua ... in Lincoln Center. , This was the largest graduating ... ceremonies Dick Woodward, AUA’s Senior Vice President for Enrollment ... and Dr. Reza Sanii, Associate Dean of Students and ...
(Date:5/24/2013)... The creative flair and design talent of graduating ... of Textiles and Clothing (ITC) have won applause from ... on 22 May at The Mira Hong Kong. ... students, various knitwear producers and yarn suppliers, the annual ... outfits from 20 graduating students majoring in knitwear design. ...
(Date:5/24/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... than adults, with signs of serious complications seen just ... "Based on the latest results, it seems like ... Dr. Jane Chiang, senior vice president of medical affairs ... are appearing faster, and it appears to be at ...
(Date:5/24/2013)... News) -- Certain statins -- the widely used ... developing type 2 diabetes, a new study suggests. ... atorvastatin (brand name Lipitor), rosuvastatin (Crestor) and simvastatin ... almost 500,000 Ontario residents, researchers in Canada found ... low in patients prescribed statins. Still, people taking ...
Breaking Medicine News(10 mins):Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 2Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 3Health News:Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles 4Health News:AUA Celebrates Seventh Annual Commencement Ceremony 2Health News:PolyU Stages Knitwear Fashion Show 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 2Health News:Type 2 Diabetes Progresses Faster in Kids, Study Finds 3Health News:Could Statins Raise Diabetes Risk? 2Health News:Could Statins Raise Diabetes Risk? 3
... a prestigious international healthcare and wellness center, will implement the ... Cypress Communications®. , ... Atlanta, GA ... healthcare and wellness center, will implement the C4 IP™ ...
... resident M. Michael Wolfe, MD, chief of the Gastroenterology ... research professor of physiology and biophysics at Boston University ... Top Doctors by Castle Connolly Medical Ltd. , The ... medical care, is a trusted and authoritative resource for ...
... been diagnosed with panic attacks or panic disorder have ... suffering a heart attack than the normal population, with ... published in Europe,s leading cardiology journal, the European ... , The study found that people who were younger ...
... WASHINGTON -- The U.S. Environmental Protection Agency should examine ... cause adverse health effects in humans, says a new ... this analysis, called a cumulative risk assessment, should consider ... effects as phthalates, instead of focusing on chemicals that ...
... prescribed for men with chronic prostatitis, a painful disorder ... significantly reduce symptoms in recently diagnosed men who had ... a clinical trial sponsored by the National Institute of ... the National Institutes of Health (NIH). The study is ...
... people know that how we live our lives effects our ... a healthy lifestyle? Why do health professionals like doctors ... public policy, health services, schools and education, the workplace, the ... support healthier living? For instance, can exercise help with addiction? ...
Cached Medicine News:Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 2Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 3Health News:MALO CLINIC Avoids Capital Expense and Gains Scalability with Hosted Unified Communications 4Health News:Boston University Medical Center gastroenterologist 2Health News:Panic attacks linked to higher risk of heart attacks and heart disease, especially in younger people 2Health News:Panic attacks linked to higher risk of heart attacks and heart disease, especially in younger people 3Health News:EPA should pursue cumulative risk assessment of phthalates and other chemicals 2Health News:EPA should pursue cumulative risk assessment of phthalates and other chemicals 3Health News:Common treatment for chronic prostatitis fails to reduce symptoms 2Health News:New Year starts with focus on healthy living 2Health News:New Year starts with focus on healthy living 3
... Vision® Plus DR Urology System provides a ... the first dedicated digital urology imaging system ... was designed to use optimized geometry and ... intensifier for maximum anatomical coverage and sharper ...
Drew Scientific has been making leading edge, top quality CBC systems for over 15 years.,The Evolution offers all the features of the Excell 16 with the new addition of primary sample tube cap pier...
... ETS™ is a therapeutic, expandable turning surface ... ,INDICATIONS , Prevention and treatment of ... to turn, Large patients using a statuc ... relief surface, Patients whose body weight and ...
... The Maxxis™ 400 is a bariatric ... safety for individuals in the home care ... 1000 lbs. (or combined weight of 2) ... depending on frame size selected , ...
Medicine Products: